GlaxoSmithKline (LSE: GSK) and Vir Biotechnology (Nasdaq: VIR) have stopped enrollment in the Phase III ACTIV trial testing VIR-7831 as a treatment for COVID-19.
The decision follows an update from trial monitors indicating that, while there were no reported safety signals, the magnitude of potential benefit was unclear.
Shares in San Francisco-based Vir tumbled over a quarter following the announcement, while GSK stock was unaffected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze